1. Home
  2. ARES vs UTHR Comparison

ARES vs UTHR Comparison

Compare ARES & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Management Corporation

ARES

Ares Management Corporation

SELL

Current Price

$127.75

Market Cap

29.1B

Sector

Finance

ML Signal

SELL

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

SELL

Current Price

$583.32

Market Cap

23.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARES
UTHR
Founded
1997
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.1B
23.9B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
ARES
UTHR
Price
$127.75
$583.32
Analyst Decision
Buy
Buy
Analyst Count
21
15
Target Price
$147.86
★ $687.14
AVG Volume (30 Days)
★ 1.9M
449.2K
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 4.15%
N/A
EPS Growth
N/A
★ 13.07
EPS
N/A
★ 18.80
Revenue
★ $4,755,618,000.00
$1,483,300,000.00
Revenue This Year
$1.36
$2.40
Revenue Next Year
$18.70
$10.58
P/E Ratio
$78.35
★ $31.27
Revenue Growth
★ 28.86
2.38
52 Week Low
$95.80
$455.63
52 Week High
$181.19
$614.23

Technical Indicators

Market Signals
Indicator
ARES
UTHR
Relative Strength Index (RSI) 48.24 52.92
Support Level $118.74 $559.33
Resistance Level $129.65 $586.61
Average True Range (ATR) 5.15 18.22
MACD -0.36 -2.82
Stochastic Oscillator 24.58 42.10

Price Performance

Historical Comparison
ARES
UTHR

About ARES Ares Management Corporation

Ares Management is one of the world's largest alternative-asset managers, with $671.3 billion in total assets under management, including $409.9 billion in fee-earning AUM, at the end of June 2026. The company has four main business segments: credit strategies ($440.5 billion in total AUM and $266.1 billion in fee-earning AUM), private equity ($24.5 billion/$13.9 billion), real estate/real assets ($151.2 billion/$88.6 billion), and other alternatives ($55.1 billion/$41.3 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: